Investment Rating - The report maintains an "Outperform" rating for the North Exchange market [5] Core Insights - The North Exchange has entered the "920 era," marking the emergence of the first ST companies [1] - The North Exchange's total number of listed companies is 265, with a total market capitalization of 737.724 billion and a circulating market capitalization of 441.839 billion, reflecting a quarter-on-quarter increase of 5.2% and 4.3% respectively [1][11] - The North Exchange 50 Index experienced a significant rebound, ending the month with a 4.72% increase, while other major indices declined [2][30] - The report highlights that 16 out of 22 industries on the North Exchange saw gains, with notable increases in beauty care, transportation, food and beverage, textiles, and agriculture, with median increases exceeding 15% [2][35] Market Overview - The North Exchange's trading volume for April was 30.945 billion shares, with a total transaction value of 630.962 billion, representing a quarter-on-quarter decrease of 14.4% and 20.2% respectively [1][17] - The average daily margin balance for April reached 5.262 billion, remaining at a historically high level [22] - As of April 30, the North Exchange 50 Index's price-to-earnings ratio (PE-TTM) was 45.31, placing it in the 99.79th percentile over the past two years [24][27] Industry Performance - The highest median price-to-earnings ratios by industry were recorded in the computer sector at 111, followed by telecommunications at 110, construction materials at 91, light industry manufacturing at 74, and social services at 72 [24][27] - The report indicates that 23 stocks reached historical highs in price during the month, with Huaguang Yuanhai achieving a remarkable 65.42% increase [2][39] Company Announcements - In April 2025, 232 companies on the North Exchange released their annual reports, with Jinbo Biological reporting the highest earnings per share at 8.27 yuan [3][12] - The report notes that there were no new listings in April, but one new stock, Tiangong Co., was issued [3][11] Policy and Important Events - The North Exchange introduced several policies in April 2025 related to refinancing, trading management, broker performance evaluation, and delisting supervision, marking a strategic move towards market independence and specialization [3][14]

具体来看，今日上榜营业部中，第一大买入营业部为国信证券股份有限公司深圳红岭中路证券营业部， 买入金额为633.49万元，第一大卖出营业部为东北证券股份有限公司黑龙江分公司，卖出金额为559.90 万元。 芭薇股份（837023）今日下跌2.02%，全天换手率25.76%，成交额2.04亿元，振幅7.40%。龙虎榜数据显 示，营业部席位合计净买入304.18万元。 北交所公开信息显示，当日该股因日换手率达25.76%上榜，营业部席位合计净买入304.18万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4826.58万元，其中，买入成交额为 2565.38万元，卖出成交额为2261.20万元，合计净买入304.18万元。 近半年该股累计上榜龙虎榜10次，上榜次日股价平均跌3.12%，上榜后5日平均跌8.28%。（数据宝） 芭薇股份4月30日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 国信证券股份有限公司深圳红岭中路证券营业部 | 633.49 | 65.94 | | 买二 | 国泰海 ...

美容护理板块午后持续拉升，芭薇股份涨超15%，丸美生物（603983）此前涨停，上海家化 （600315）、百亚股份（003006）跟涨。 ...

证券代码：837023 证券简称：芭薇股份 公告编号：2025-038 广东芭薇生物科技股份有限公司 持股 5%以上股东减持股份结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、减持主体减持前基本情况 | 股东名称 | 股东身份 | | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 广州云美产业投资合 | 持 股 | 5% 以 | 7,142,857 | 8.33% | 北京证券交易所上市 | | 伙企业（有限合伙） | 上股东 | | | | 前取得 | 二、减持计划的实施结果 三、备查文件目录 | | | | | | 减持价格区 | | 减 | 当前持股 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 间 | | 持 | 数量（股） | | | | | 已减 | 减 | | | | 计 | | ...

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company achieved a revenue of 695 million yuan in 2024, representing a year-on-year growth of 48.3%, and a net profit of 45 million yuan, up 10.3% year-on-year, which met expectations [7] - The company plans to distribute a cash dividend of 3.0 yuan per share (including tax) for 2024, with a distribution ratio of 56.71% [7] - In Q1 2025, the company reported a revenue of 162 million yuan, a year-on-year increase of 40.1%, and a net profit of 9 million yuan, up 8.8% year-on-year, slightly below expectations [7] - The company is focusing on a major client strategy and has formed partnerships with emerging brands to drive revenue growth, with domestic revenue reaching 642 million yuan in 2024, a 40.5% increase [7] - The company is enhancing its raw material research and investment to improve integrated capabilities and increase the value-added of its OEM services [7] - The profit forecast for 2025-2027 has been adjusted downwards, with expected net profits of 69 million yuan, 91 million yuan, and 115 million yuan respectively [7] Financial Data and Profit Forecast - Total revenue is projected to reach 1,009 million yuan in 2025, with a year-on-year growth rate of 45.2% [6] - The gross profit margin is expected to be 26.4% in 2025, with a net profit margin of 6.5% [6] - The company’s return on equity (ROE) is forecasted to be 15.6% in 2025 [6] - The earnings per share (EPS) is projected to be 0.81 yuan in 2025 [6]

Core Viewpoint - The "climax needle" concept has led to significant stock price fluctuations in related companies, highlighting the volatility and speculative nature of the medical beauty industry [1][4]. Group 1: Market Reaction - On April 28, after the opening of A-shares, stocks related to the "climax needle" concept experienced a collective decline, with Bawei Co. (837023) dropping over 9%, Demei Chemical (002054.SZ) down more than 7%, and Tianyuan Co. (002386.SZ) falling over 5% [1]. - Prior to the decline, these stocks had surged due to speculation surrounding the "climax needle," with some reaching their daily limit [1]. Group 2: Product Details - The "climax needle" is marketed as an injection of collagen at sensitive points within the female vagina, with prices ranging from thousands to tens of thousands of yuan [1]. - A specific product developed by Yuanxiang Biotechnology is priced at 9,800 yuan per injection and is classified as a "platelet-rich plasma preparation device" (PRP), which is a strictly regulated Class III medical device [3]. Group 3: Medical and Regulatory Insights - PRP technology involves extracting a patient's blood, processing it to concentrate platelets, and utilizing growth factors for tissue repair and regeneration [3]. - While PRP has been increasingly applied in the medical beauty sector, the National Medical Products Administration has not yet issued clear approvals for its use in facial injections, despite existing clinical literature [3][4]. - Experts have criticized the "climax needle" as lacking scientific support and warned of potential risks associated with its use, indicating a need for regulatory scrutiny in the medical beauty industry [1][4].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.5300 | 0.5400 | -1.85 | 0.5000 | | 每股净资产（元） | 4.66 | 4.27 | 9.13 | 4.09 | | 每股公积金(元) | 2.32 | 2.13 | 8.92 | 2.09 | | 每股未分配利润(元) | 1.22 | 1.06 | 15.09 | 0.96 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 6.95 | 4.69 | 48.19 | 4.59 | | 净利润(亿元) | 0.45 | 0.41 | 9.76 | 0.38 | | 净资产收益率(%) | 12.15 | 12.85 | -5.45 | 12.59 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | -- ...

广东芭薇生物科技股份有限公司 审计报告 天 职 业 字 [2025]14607 号 目 录 审计报告 -- -1 2024 年度财务报表— -6 2024 年度财务报表附注— -18 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.eon.cn） 审计报告 天职业字[2025]14607 号 广东芭薇生物科技股份有限公司全体股东: 一、审计意见 我们审计了广东芭薇生物科技股份有限公司(以下简称"广东芭薇")财务报表,包括 2024 年 12 月 31 日的合并及母公司资产负债表,2024年度的合并及母公司利润表、合并及母公司现 金流量表、合并及母公司股东权益变动表以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了广 东芭薇 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并及母公司经营成果和 现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对财 务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职业道 德守则 ...

可持续发展报告 以绿色创新 守护自然之美 | 环境责任 | 31 | | --- | --- | | 环境表现 | 33 | | 应对气候变化 | 35 | | 污染防治与生态系统保护 | 38 | | 污染物排放 | 40 | | 废弃物处理 | 41 | | 生态系统与生物多样性保护 | 42 | | 环境合规管理 | 43 | | 资源利用 | 44 | | 能源利用 | 46 | | 水资源利用 | 48 | | 循环经济 | 49 | | 以生态共建 | | | --- | --- | | 塑造健康之美 | | | 可持续发展管理 | 21 | | 可持续发展管理 | 23 | | 可持续发展战略 | 24 | | 利益相关方沟通 | 28 | | 可持续发展议题重要性评估 | 30 | | 以企业担当 | | | --- | --- | | 赋能社会之美 | | | 社会责任 | 51 | | 员工关怀 | 53 | | 供应链管理 | 66 | | 创新驱动 | 71 | | 客户价值 | 75 | | 乡村振兴 | 79 | | 社会贡献 | 79 | 以透明治理 铸就信任之美 | 公司治理 ...

广东芭薇生物科技股份有限公司 2024 年度控股股东及其他关联方资金占用情况的专项说明- -1 2024 年度非经营性资金占用及其他关联资金往来情况汇总表— -2 2024 年度控股股东及其他关联方资金 占用情况的专项说明 天职业字[2025]14607-3 号 m 录 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行 报告编码:京25J2DS4 控股股东及其他关联方资金占用情况的专项说明 天职业字[2025]14607-3 号 广东芭薇生物科技股份有限公司董事会: 我们审计了广东芭薇生物科技股份有限公司(以下简称"广东芭薇公司")财务报表,包 括2024年12月31日的合并及母公司资产负债表、2024年度的合并及母公司利润表、合并及母公 司现金流量表、合并及母公司股东权益变动表以及财务报表附注，并于2025年4月24日签署了 标准无保留意见的审计报告。 根据中国证监会、公安部、国资委、中国银保监会《上市公司监管指引第8号 --- 上市公 司资金往来、对外担保的监管要求》和证券交易所相关文件要求,广东芭薇公司编制了后附的 2024年度非经营性资金占用及 ...